Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:05:54 EST Sat 17 Jan 2026
Enter Symbol
or Name
USA
CA



Q:HURA - TUHURA BIOSCIENCES INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
HURA - Q0.20.68·6.755.00.7605-0.0078-1.0271.41331,3170.7608  0.7799  0.75175.27  0.7019:35:48Dec 1515 min RT 2¢

Recent Trades - Last 10 of 1317
Time ETExPriceChangeVolume
19:35:48Q0.77640.0163,000
17:48:06Q0.77640.01622
17:27:09Q0.77640.0162
17:23:23Q0.77570.01532
17:16:31Q0.76050.0001318
16:41:11Q0.77990.019584
16:10:04Q0.76050.00011
16:04:45Q0.76050.00011
16:04:45Q0.76050.00011
16:04:06Q0.76050.00011

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-15 07:50U:HURANews ReleaseTuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
2025-12-11 07:30U:HURANews ReleaseTuHURA Biosciences Provides Corporate Update Following Recent Financing
2025-12-09 09:49U:HURANews ReleaseTuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
2025-12-08 07:50U:HURANews ReleaseTuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
2025-11-14 19:53U:HURASEDAR Interim MD & ASEDAR Interim MD & A
2025-11-14 19:48U:HURASEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-11-14 07:00U:HURANews ReleaseTuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
2025-11-03 09:01U:HURANews ReleaseTuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
2025-08-20 08:00U:HURANews ReleaseTuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
2025-08-14 20:36U:HURASEDAR Interim Financial StatementsSEDAR Interim MD & A
2025-08-14 16:15U:HURANews ReleaseTuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
2025-07-01 08:50U:HURANews ReleaseTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000(TM) and Russell 2000(TM) Indexes
2025-06-30 08:50U:HURANews ReleaseTuHURA Biosciences Completes Acquisition of Kineta
2025-06-24 08:00U:HURANews ReleaseTuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda(TM) (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
2025-06-23 17:00U:HURANews ReleaseTuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
2025-06-09 08:00U:HURANews ReleaseFDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
2025-06-03 09:58U:HURANews ReleaseTuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy
2025-06-02 08:03U:HURANews ReleaseTuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
2025-05-23 18:24U:HURASEDAR Annual ReportSEDAR Annual Report
2025-05-15 18:51U:HURASEDAR Interim Financial StatementsSEDAR Interim MD & A